ArticleFrontiers in immunology2025
Methionine enkephalin upregulates toll-like receptors in macrophages to suppress severe fever with thrombocytopenia syndrome virus infection.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe fever with thrombocytopenia syndrome virus (SFTSV) is a newly identified tick-borne virus with a high case fatality rate. Currently, no specific antiviral drugs are available for its treatment. Methionine enkephalin (MENK) has the ability to enhance immune cell function nonspecifically. This study investigated the mechanism by which MENK regulates macrophages to exert antiviral effects against SFTSV infection. Methods: An SFTSV-infected RAW264.7 macrophage model pretreated with MENK was developed. RNA sequencing was employed to analyze transcriptomic alterations and identify differentially expressed genes (DEGs). Subsequent experimental validation based on bioinformatics analysis was performed on key DEGs. Results: The DEGs between the MENK-SFTSV and SFTSV groups were mainly enriched in several signaling pathways, including the Toll-like receptor (TLR) signaling pathway (ko04620), IL-17 signaling pathway (ko04657), TNF signaling pathway (ko04668), and interaction between viral proteins and cytokines and their receptors (ko04061). Key genes included TLR7, TLR3, TLR8, TLR9, activator protein-1 (AP-1), IL-17RA, TNF-α, IL-1β, CCR5, and CXCL10, all of which successfully docked with the MENK molecule. Compared with the TLR7 agonist imiquimod (IMQ), MENK demonstrated a greater advantage in modulating macrophages to resist SFTSV infection. MENK and the TLR7 agonist imiquimod can upregulate the expressions of TLR7, TLR3, AP-1, and IL-17RA. In addition, MENK significantly upregulated the levels of TLR9, TLR8, IL-1β, TNF-α, CCR5, and CXCL10. Conclusion: MENK upregulated the expression levels of the pattern recognition receptors and cytokine receptors; promoted the nuclear transcription to modulate cellular immune responses; and increased the levels of the cytokines to induce inflammatory responses against SFTSV infection. Notably, MENK possessed unique advantages and exhibited efficacy comparable to IMQ in restoring antiviral immunity, suggested that MENK emerged as a promising host-directed therapeutic candidate or vaccine prototype against SFTSV infection, warranting further preclinical and clinical investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.